PLIANT THERAPEUTICS INC
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
PLRX$0.80-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
| March 31,2025 | *December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $91,936 | $71,188 |
| Short-term investments | 213,709 | 284,536 |
| Prepaid expenses and other current assets (Note 5) | 5,546 | 6,540 |
| Total current assets | 311,191 | 362,264 |
| Property and equipment, net (Note 4) | 5,240 | 5,525 |
| Operating lease right-of-use assets (Note 15) | 26,430 | 27,243 |
| Restricted cash | 1,482 | 1,482 |
| Other non-current assets | 427 | 435 |
| Total assets | $344,770 | $396,949 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $5,622 | $5,960 |
| Accrued research and development | 14,381 | 14,363 |
| Accrued liabilities (Note 6) | 7,429 | 12,353 |
| Operating lease liabilities, current (Note 15) | 771 | 542 |
| Total current liabilities | 28,203 | 33,218 |
| Operating lease liabilities, non-current (Note 15) | 29,119 | 29,439 |
| Long-term debt (Note 7) | 30,284 | 30,211 |
| Total liabilities | 87,606 | 92,868 |
| Commitments and Contingencies (Note 14) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at March 31, 2025 and December 31, 2024, 300,000 shares designated as Series A Junior Participating Preferred Stock at March 31, 2025 and none designated as Series A Junior Participating Preferred Stock at December 31, 2024; and none issued or outstanding at March 31, 2025 and December 31, 2024 (Note 8 and 10) | — | — |
| Common stock, $0.0001 par value per share; 300,000,000 shares authorized at March 31, 2025 and December 31, 2024; and 61,386,183 and 60,860,838 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively; (Note 9) | 6 | 6 |
| Additional paid-in capital | 1,023,217 | 1,013,806 |
| Accumulated deficit | (766,218) | (710,052) |
| Accumulated other comprehensive gain | 159 | 321 |
| Total stockholders’ equity | 257,164 | 304,081 |
| Total liabilities and stockholders’ equity | $344,770 | $396,949 |
*The condensed balance sheet as of December 31, 2024 has been derived from the audited financial statements as of that date.
The accompanying notes are an integral part of these condensed financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.